Immunic, Inc. (IMUX)
Automate Your Wheel Strategy on IMUX
With Tiblio's Option Bot, you can configure your own wheel strategy including IMUX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IMUX
- Rev/Share 0.0
- Book/Share 0.2004
- PB -13.5714
- Debt/Equity -0.0397
- CurrentRatio 0.7414
- ROIC 19.8964
- MktCap 67838790.0
- FreeCF/Share -0.8175
- PFCF -0.8188
- PE -0.7443
- Debt/Assets 0.0102
- DivYield 0
- ROE -3.2695
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | IMUX | William Blair | -- | Outperform | -- | -- | March 25, 2025 |
| Resumed | IMUX | Leerink Partners | -- | Outperform | -- | $5 | Sept. 9, 2024 |
| Initiation | IMUX | B. Riley Securities | -- | Buy | -- | $6 | Aug. 27, 2024 |
News
Immunic completes patient enrollment in Phase 3 relapsing multiple sclerosis trials
Published: June 05, 2025 by: Proactive Investors
Sentiment: Positive
Immunic Inc (NASDAQ:IMUX) has announced the completion of enrollment for both phase 3 ENSURE trials of its lead asset, vidofludimus calcium (IMU-838), in relapsing multiple sclerosis (RMS). The ENSURE program includes two identical, multicenter, randomized, double-blind phase 3 trials, ENSURE-1 and ENSURE-2, designed to assess the efficacy, safety, and tolerability of vidofludimus calcium compared to placebo in patients with RMS.
Read More
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
Published: June 05, 2025 by: PRNewsWire
Sentiment: Neutral
– Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 – – Additional Data from Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis Further Supports the Recently Released Positive Top-Line Results and Further Underlines Vidofludimus Calcium's Neuroprotective Potential – – New CALLIPER Data Regarding Time to 24-Week Confirmed Disability Worsening Shows Substantial and Medically Relevant Reductions for Vidofludimus Calcium Over Placebo in the Overall Study Population and Major Disease Subtypes – NEW YORK , June 5, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a …
Read More
Immunic to Participate in Investor, Scientific and Industry Conferences in June
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 2, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor, scientific and industry conferences in June: June 3-5: Jefferies Healthcare Conference. Daniel Vitt, Ph.D.
Read More
Immunic reports reduced disability worsening in progressive multiple sclerosis trial
Published: April 30, 2025 by: Proactive Investors
Sentiment: Positive
Immunic Inc (NASDAQ:IMUX) has reported promising results from its Phase 2 CALLIPER trial of vidofludimus calcium, which showed a 30% reduction in the risk of 24-week confirmed disability worsening in patients with primary progressive multiple sclerosis (PPMS) compared to placebo. The study enrolled 467 patients with progressive multiple sclerosis (PMS), including subpopulations with PPMS and non-active secondary progressive multiple sclerosis.
Read More
Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
Published: April 30, 2025 by: PRNewsWire
Sentiment: Neutral
– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Population of Primary Progressive Multiple Sclerosis – – Showed Consistent Reduction of Disability Worsening in Subpopulations Without Inflammatory Lesions at Baseline in Overall Study Population; Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events in Patients Without Gadolinium-Enhancing Lesions at Baseline by 29% Compared to Placebo – – Reduced Annualized Rate of Thalamic Brain Volume Loss by 20% Compared to Placebo – – Confirmed Favorable Safety and Tolerability Observed in Previous Clinical …
Read More
Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher
Published: April 28, 2025 by: Seeking Alpha
Sentiment: Positive
Immunic's lead asset, vidofludimus calcium, shows promise in MS trials, with positive interim results and potential for commercialization if upcoming catalysts deliver. Despite high volatility and recent stock dilution, Immunic's market cap remains low, suggesting significant upside if clinical trials succeed. Vidofludimus calcium's unique dual action offers neuroprotection and anti-inflammatory benefits, positioning it as a potential next-gen oral MS treatment.
Read More
Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
Published: April 10, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 10, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the closing of its previously announced registered direct offering of 5,666,667 shares of its common stock at a price of $0.90 per share, led by Aberdeen Investments. All securities in the offering were sold by Immunic.
Read More
Biotechs challenge big pharma with new oral weight loss therapies
Published: February 28, 2025 by: Proactive Investors
Sentiment: Positive
With the smash success of glucagon-like peptide-1 (GLP-1) agonists as a treatment for obesity, pharmaceutical giants and emerging biotechnology firms alike are working to develop an equally effective option in the form of pills. The weight loss drug market, projected by Goldman Sachs to reach $130 billion by 2030, represents a significant opportunity for drugmakers.
Read More
Immunic to highlight vidofludimus calcium's potential as MS therapy at upcoming forum
Published: February 26, 2025 by: Proactive Investors
Sentiment: Positive
Immunic Inc (NASDAQ:IMUX) announced that it will present key data for its investigational drug vidofludimus calcium in two poster presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025. "Having two poster presentations on vidofludimus calcium at the prestigious ACTRIMS Forum highlights the unique importance of our drug candidate and its promise as a potential new treatment option for multiple sclerosis (MS)," Immunic CEO Dr Daniel Vitt said in a statement.
Read More
Immunic highlights IMU-856's potential as weight management therapy
Published: February 20, 2025 by: Proactive Investors
Sentiment: Positive
Immunic Inc (NASDAQ:IMUX) has released new data that supports the potential of its investigational therapeutic IMU-856 as an oral treatment for weight management. IMU-856, a small molecule that targets SIRT6, demonstrated a dose-dependent increase in endogenous glucagon-like peptide-1 (GLP-1) levels in a post hoc analysis of patients from a phase 1b clinical trial in celiac disease.
Read More
Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
Published: February 20, 2025 by: PRNewsWire
Sentiment: Neutral
– New Data Suggests that IMU-856 Could Be a Potential Oral Treatment Option for Weight Management; Program Is Phase 2 Ready – – Dose-Dependent Increase of Endogenous GLP-1 Levels Observed in Post Hoc Analysis of Patients From Phase 1b Clinical Trial in Celiac Disease – – Dose-Dependent Reduction of Body Weight Gain and Food Consumption Observed in Preclinical Study – – Webcast to be Held Today, February 20 at 8:00 am ET – NEW YORK , Feb. 20, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic …
Read More
About Immunic, Inc. (IMUX)
- IPO Date 2014-04-17
- Website https://www.immunic-therapeutics.com
- Industry Biotechnology
- CEO Dr. Daniel Vitt Ph.D.
- Employees 91